ArticleOncotarget2019

Correction: First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL.

John C Byrd et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.